June 1999
Founded Kolon TissueGene
Foundation1999 - 2002
June 2000
License Agreement with Kolon Life Science
October 2001
Secured US Patent with TG-C Related Technology (Gene Therapy Utilizing TGF-β1)
Early Phase Clinical TrialsGrowth 2003 - 2012
September 2004
Obtained US patent related to TG-C(USP 6,797,703) "Gene therapy using TGF-β1"
August 2005
Selected as a National Project by Korean Ministry of Trade, Industry and Energy
December 2006
Clearance for US Phase I Clinical Trial
April 2009
Completed Administration of Patients for US Phase I
November 2010
Clearance for US Phase II Clinical Trial
October 2012
Completed Administration of Patients for US Phase II
US Clinical Trials & CommercializationRapid Progress 2013~
May 2015
Clearance for US Phase III Clinical Trial (SPA)
November 2015
Appointed as a Global Innovative Biotherapeutics Technology Development Research Center
May 2016
Equity Investment of K-EXIM Bank
November 2016
Sublicense Agreement between Kolon Life Science and Japanese Mitsubishi Tanabe
April 2017
Secured AA Grade from Technology Assessment by NICE
November 2017
Listed on KOSDAQ stock market in Korea
March 2018
Changed company name, Kolon TissueGene, Inc.
December 2021
Clearance for US Phase II Clinical Trial (HIP OA)
Resume TG-C Phase III Clinical Trial (Knee OA)